Haduvio™: Relief is Possible
We are developing Haduvio™ (nalbuphine ER) unlocking new market opportunities and the potential to significantly improve the quality of life of patients suffering from the serious symptoms associated with chronic neurologically mediated conditions.
Passionate about Progress
Backed by expert scientific and medical advisors and dedicated to our investors, the Trevi leadership team is highly engaged and experienced in life science clinical development, successful commercialization, and building companies of exceptional value.
Passionate about Progress
Backed by expert scientific and medical advisors and dedicated to our investors, the Trevi leadership team is highly engaged and experienced in life science clinical development, successful commercialization, and building companies of exceptional value.
A New Hope for Patients with Chronic and Serious Neurologically Mediated Conditions
We are developing Haduvio™ as an oral treatment for a broad range of chronic conditions for which patients have few, if any, treatment options. With its unique dual mechanism of action, Haduvio™ has the potential to significantly improve the quality of life of patients.
Committed to Excellence in Pharmaceutical Development and Bringing Solutions to Patients
news
11/11/2020
PRISM Trial of Haduvio ™ for Severe Pruritus in Patients with Prurigo Nodularis Exceeds Halfway Enrollment Milestone Phase 2 Chronic Cough Trial in Patients with IPF Enrolled First New Subject Post- COVID -19 Restrictions Cash Position Expected to Fund Operations into the First Half of 2022 NEW
11/10/2020
NEW HAVEN, Conn. , Nov. 10, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management
11/04/2020
Conference Call and Webcast to be Held at 4:30 p.m. ET NEW HAVEN, Conn. , Nov. 04, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious
